KMT2A-REARRANGED
Clinical trials for KMT2A-REARRANGED explained in plain language.
Never miss a new study
Get alerted when new KMT2A-REARRANGED trials appear
Sign up with your email to follow new studies for KMT2A-REARRANGED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare leukemia: drug combo enters first human tests
Disease control Not yet recruitingThis early-stage trial tests whether combining two drugs, blinatumomab and revumenib, is safe for people with a rare form of acute lymphoblastic leukemia (ALL) caused by a KMT2A gene change. The study will enroll 20 adults, including those whose cancer has returned or not respond…
Matched conditions: KMT2A-REARRANGED
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:18 UTC
-
New drug combo aims to tackle Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-stage study tests two experimental drugs, ziftomenib and mezigdomide, given together to adolescents and adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose and check for side…
Matched conditions: KMT2A-REARRANGED
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 04:37 UTC